SCHEMBL485577

SCHEMBL485577

O=Cc1ccc(F)c2ccccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 5/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
LMNA P02545 1/20 0.46
THRB P10828 1/20 0.46
BLM P54132 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
CYP2A6 P11509 2/20 0.41
IMPDH2 P12268 2/20 0.41
ALDH1A1 P00352 4/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KDM4E B2RXH2 1/20 0.39
NPC1 O15118 1/20 0.39
HSP90AA1 P07900 1/20 0.39
IDO1 P14902 1/20 0.39
RAB9A P51151 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PPARG P37231 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29951202 1.00 ERN1 (0.47) ERN1MEN1KMT2ALMNATHRB
Hydrochloric Acid SCHEMBL28960226 0.98 ERN1 (0.45) ERN1MEN1KMT2ALMNATHRB
SCHEMBL9671258 0.86 ERN1 (0.57) ERN1MEN1KMT2ALMNATHRB
SCHEMBL12143561 0.86 ERN1 (0.57) ERN1MEN1KMT2ALMNATHRB
SCHEMBL982388 0.85 KMT2A (0.61) MEN1KMT2ALMNATHRBBLM
SCHEMBL29786760 0.85 KMT2A (0.61) MEN1KMT2ALMNATHRBBLM
SCHEMBL6757215 0.77 ALDH1A1 (0.38) LMNAALDH1A1HTTKDM4ENPSR1
SCHEMBL13747587 0.77 NFE2L2 (0.36) LMNAALDH1A1HTTKDM4ENPSR1
SCHEMBL31596866 0.77 ALDH1A1 (0.38) LMNAALDH1A1HTTKDM4ENPSR1
SCHEMBL6562728 0.77 HPRT1 (0.46) LMNATDP1CYP2A6ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107188851-B Method for synthesizing astemizole key intermediate and derivative thereof 湖南大学 2020-04-07 CN claimed
US-5877321-A NEUROKININ RECEPTOR SANOFI (FR) 1999-03-02 US claimed
WO-2025118034-A1 COMPOUNDS ACTIVE AT THE SEROTONERGIC 5-HT2A RECEPTOR Psylo Pty Ltd (AU) 2025-06-12 WO disclosed
US-20230142739-A1 PROTEIN-PROTEIN INTERACTION STABILIZERS UNIV CALIFORNIA (US) 2023-05-11 US disclosed
EP-3464317-B1 AMINOSTEROID DERIVATIVES AND PROCESS FOR PRODUCING SAME UNIV LAVAL (CA) 2023-04-26 EP disclosed
CN-115947756-A Method for synthesizing polyfluoroalkyl aryl ether by directly coupling aryl halide and polyfluoroalkyl alcohol 西湖大学 2023-04-11 CN disclosed
EP-4125861-A2 PROTEIN-PROTEIN INTERACTION STABILIZERS The Regents of the University of California (US) 2023-02-08 EP disclosed
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2022-05-24 US disclosed
US-11174282-B2 Aminosteroid derivatives and process for producing same UNIVERSITé LAVAL (CA) 2021-11-16 US disclosed
WO-2021203016-A2 PROTEIN-PROTEIN INTERACTION STABILIZERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-10-07 WO disclosed
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2021-08-05 US disclosed
EP-1192143-A1 RHODANINE DERIVATIVES FOR USE IN A METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-04-03 EP disclosed
EP-1167366-A1 AMINE DERIVATIVES Sankyo Company, Limited (JP) 2002-01-02 EP disclosed
CN-1062859-C Substd. 1-naphthoyl guanidines, their preparing method, use and drug contg. them HOECHST AG (DE) 2001-03-07 CN disclosed
WO-2000076987-A1 RHODANINE DERIVATIVES FOR USE IN A METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO disclosed
US-5877321-A NEUROKININ RECEPTOR SANOFI (FR) 1999-03-02 US disclosed
CN-1167758-A Substd. 1-naphthoyl guanidines, their preparing method, use and drug contg. them HOECHST AG (DE) 1997-12-17 CN disclosed
US-5446052-A Used for treatment of substance p-and neurokinin-dependent pathology such as analgesia and inflmmation SANOFI (FR) 1995-08-29 US disclosed
US-5300648-A Analgesics, antiinflammatory agents SOCIETE ANONYME: ELF SANOFI (FR) 1994-04-05 US disclosed
EP-0512902-A1 Dialkyleneperidino compounds and their enantiomers, process for their preparation and pharmaceutical compositions containing them SANOFI (FR) 1992-11-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF RHEB, KRAS, NRAS ERN1 3870/4885MEN1 254/4885KMT2A 2481/4885
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof RHEB, GDI2, KRAS ERN1 1744/4885MEN1 169/4885KMT2A 3149/4885
US-20230142739-A1 PROTEIN-PROTEIN INTERACTION STABILIZERS HSPBP1, HSPA8, HSPH1 ERN1 1193/4885MEN1 3934/4885KMT2A 3385/4885
US-11174282-B2 Aminosteroid derivatives and process for producing same HSD17B11, HSD17B7, CYP19A1 ERN1 2951/4885MEN1 1439/4885KMT2A 3255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.